Clinical Trial Update: Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

Phase II study evaluating blinatumomab for patients with minimal residual disease in B-precursor acute lymphoblastic leukemia has completed with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)

Snippet

Sponsor: Amgen Research (Munich) GmbH | Conditions: Acute Lymphoblastic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2015-01-07